ICL Acquires Majority of Lavie Bio's Activities and Assets from Evogene
July 8, 2025
ICL Group Ltd. has completed the acquisition of the majority of activities and assets of Lavie Bio Ltd., Evogene's ag-biologicals subsidiary, including Lavie Bio's BDD technology platform, microbial bank, pipeline and current commercial products. Evogene also transferred its MicroBoost AI tech-engine for agriculture to ICL as part of the divestiture; Lavie Bio core personnel will move to ICL while certain strategic partnerships remain with Lavie Bio.
- Buyers
- ICL Group Ltd.
- Targets
- Lavie Bio Ltd.
- Sellers
- Evogene Ltd.
- Industry
- Biotechnology
- Location
- Israel
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
IK Partners Acquires Majority Stake in BIOBank
May 29, 2024
Medical Devices
IK Partners (via its IK Small Cap III fund) has agreed to acquire a majority stake in French tissue bank BIOBank from Verto Growth, Capital Croissance and management, who will reinvest. BIOBank, headquartered in Lieusaint, France, is a leading processor and distributor of bone allografts for orthopaedic, spine, dental and cranio‑maxillofacial surgery; IK plans to support market-share gains in France, accelerate international expansion and pursue a buy‑and‑build strategy.
-
Leinco Technologies Acquires QED Biosciences from Genovis
September 3, 2024
Biotechnology
Leinco Technologies, a portfolio company backed by Ampersand Capital Partners, has acquired Genovis-owned QED Biosciences to expand its catalog of antibodies, recombinant proteins and IVD raw materials. The deal transfers Genovis' antibody business to Leinco and strengthens Leinco's antibody development and IVD support capabilities for research and diagnostics customers worldwide.
-
OmniActive Health Technologies Acquires ENovate Biolife
November 4, 2024
Food & Beverage
OmniActive Health Technologies has acquired ENovate Biolife to expand its portfolio of clinically validated botanical and specialty active ingredients for dietary supplements, functional foods and sports nutrition. The acquisition strengthens OmniActive's R&D, clinical and commercial capabilities and aims to accelerate global distribution of ENovate's ingredients such as Muvz, RedNite and Oxyjun.
-
Verdesian Life Sciences Acquires Cytozyme Laboratories
April 27, 2021
Agriculture
Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.
-
Invaio Sciences Acquires Peptyde Bio
December 7, 2023
Biotechnology
Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.
-
Agilent Technologies Acquires Avida Biomed
January 4, 2023
Biotechnology
Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.